| Metric | Details |
|---|---|
| Entity / Legal Name | CSL Plasma Inc. |
| Parent Company | CSL Behring LLC / CSL Limited (ASX: CSL) |
| S&P / Moody’s Rating (CSL Behring) | A‑ / A3 |
| Outlook | Stable |
| Investment Grade Status | Investment Grade — Upper-Medium Grade |
| Sector | Plasma Collection / Biopharmaceuticals |
| US Center Count | 300+ |
| Cap Rate Range | 5.25–6.25% |
| Typical Lease Term | 10–20 years (NNN) |
| Guarantee Type | CSL Plasma Inc. (CSL Behring subsidiary) |
| Parent Annual Revenue | ~$14.8B AUD (~$9.5B USD, CSL Limited FY2024) |
| Typical Building Size | 8,000–15,000 SF |
| Typical Price Range | $3,000,000–$7,500,000 |
CSL Plasma Business Overview & NNN Investment Profile
CSL Plasma Inc. is one of the two largest plasma collection networks in the United States, operating over 300 plasma donation centers that supply raw source plasma to its parent CSL Behring — the plasma-derived biopharmaceuticals division of Australian biotechnology giant CSL Limited (ASX: CSL). CSL Behring is a global leader in plasma-derived medicines for rare and life-threatening diseases including hemophilia, immune deficiencies, neurological conditions, and hereditary angioedema. The US plasma collection network is the critical supply chain input for CSL Behring’s manufacturing operations and carries A‑/A3 upper-medium investment grade credit support from the parent.
The Plasma Collection NNN Investment Case
CSL Plasma centers represent one of the most compelling intersections of essential healthcare services and accessible NNN investment pricing. The plasma collection model creates extraordinarily sticky locations — CSL builds loyal donor communities over years, with regular donors (visiting up to twice weekly) creating a recurring revenue base that is fundamentally different from volume-sensitive urgent care or discretionary-dependent dental concepts. When a CSL Plasma center signs a long-term NNN lease, it is committing to a location that is integral to its supply chain — not merely a service delivery point.
The global demand for plasma-derived medicines is structural and growing. Aging populations, expanding indications for immunoglobulin therapies, and increasing diagnosis rates for rare diseases supported by CSL’s products create secular tailwinds for plasma collection volume that are independent of economic cycles.
CSL Plasma NNN Lease Structure & Cap Rates
CSL Plasma NNN leases carry 10 to 20 year initial terms with 2% to 3% annual rent escalations. The 8,000 to 15,000 SF format in suburban commercial corridors with strong accessibility and parking is standard. Cap rates for CSL Plasma NNN properties trade between 5.25% and 6.25% as of Q1 2026 — tighter than BioLife Plasma (BBB‑/Baa3 at 5.75% to 6.75%) reflecting the stronger A‑/A3 parent credit. Acquisition prices of $3,000,000 to $7,500,000 make these accessible for individual investors seeking upper-medium investment-grade healthcare NNN.
Comparable NNN Tenants
| Comparable Tenant | Rating | Cap Rate Range |
|---|---|---|
| BioLife Plasma (Takeda) | BBB‑ / Baa3 | 5.75–6.75% |
| Grifols Plasma | BB / Ba3 | 7.00–8.50% |
| Concentra | BBB+ / Baa3 | 5.50–6.50% |
Is CSL Plasma investment grade?
Yes. CSL Plasma is a subsidiary of CSL Behring, which carries A‑ from S&P and A3 from Moody’s — upper-medium investment grade. CSL Plasma is the highest-rated plasma collection NNN tenant in the US market.
What cap rates are CSL Plasma NNN properties trading at?
CSL Plasma NNN properties trade at 5.25% to 6.25% as of Q1 2026 — tighter than BioLife (BBB‑/Baa3) reflecting the stronger A‑/A3 parent credit. Acquisition prices range from $3,000,000 to $7,500,000.
The Only CSL Plasma NNN Advisor Whose Fee Comes From the Deal, Not From You
In NNN buyer representation, the listing broker typically pays a cooperating commission to the buyer’s broker. On the majority of transactions, this means there is no separate fee to you as the buyer. Where a cooperating commission is not available, our compensation is agreed upon with you in advance so there are never surprises.
Find It — CSL Plasma NNN centers sourced with entity guarantee confirmation, donor traffic analysis, and lease term review.
Fund It — A‑/A3 biopharma-backed healthcare credit. Life companies compete aggressively for this credit and format.
Exit It — Selling a CSL Plasma property? Upper-medium investment-grade healthcare at accessible price points drives strong demand.
Get Your Free CSL Plasma NNN Consultation →
In a 1031 exchange? Tell us your timeline — we move faster.
Related NNN Tenants
- Ascension
- Aspen Dental
- Athletico
- BioLife Plasma
- Concentra / Humana
- Corewell Health
- DaVita Dialysis
- EyeCare Partners
- Fresenius
- Grifols
- Henry Ford Health
- HCA Healthcare
- Heartland Dental
- Mary Washington Healthcare
- McLaren Health Care
- Oak Street Health
- Piedmont Healthcare
- Sparrow Health
- Trinity Health
- U of M Health
- University of Pittsburgh Medical Center (UPMC)
- Acadia Healthcare
- AFC Urgent Care
- ATI Physical Therapy
- CityMD / Summit Health
- Encompass Health
- Fast Pace Urgent Care
- MedExpress Urgent Care
- MyEyeDr
- NextCare Urgent Care
- Octapharma Plasma
- Pacific Dental Services
- Select Physical Therapy
- Smile Brands
- VCA Animal Hospitals
- WellNow Urgent Care
- Banfield Pet Hospital
- Labcorp
- National Vision
- Quest Diagnostics
Own a CSL Plasma Property? Capital Markets Strategies Beyond Selling
Maturing debt and considering refinancing? Our capital markets team maintains 150+ lender relationships underwriting NNN properties across investment-grade and non-investment-grade credit tiers. We structure rate-and-term refinancing, cash-out refis, and bridge-to-perm takeouts.
Evaluating a 1031 exchange or disposition? We represent both sides of CSL Plasma NNN transactions — whether you are looking to exit at peak value, exchange into a higher-quality credit tenant, or reposition within the same sector.
Need a current valuation? We maintain live comps on CSL Plasma NNN transactions and can produce a Broker Opinion of Value within 48 hours reflecting today’s cap rate market.
Own multiple CSL Plasma properties? Considering an off-market sale?
Investment Grade represents owners on confidential disposition of CSL Plasma portfolios and individual properties through off-market direct-to-principal distribution to specialty REITs, private equity funds, and family offices. CSL Plasma buyer demand runs deep, and portfolio sales consistently produce stronger pricing than sequential individual sales because the institutional buyer pool is structured around portfolio acquisition.
For multi-property owners considering a portfolio disposition, see Selling Investment Grade NNN Off-Market: Tenant-by-Tenant Buyer Demand. For the full off-market framework covering individual property dispositions, sale-leasebacks, and 1031 coordination, see Off-Market CRE Sales: The Complete 2026 Guide.
The pre-listing conversation is at no cost and fully confidential. Email team@investmentgrade.com or see contact Investment Grade.
